Clinical Trial: NCT02030834
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2023-06-22 |
Study Overview
Brief Summary
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019 cells) in non-Hodgkins Lymphoma (NHL) patients. The duration of active protocol intervention is approximately 24 months from screening visit. The protocol will require approximately 48 months to complete.
Official Title
Conditions
Intervention / Treatment
- Biological: CART-19
Other Study ID Numbers
- UPCC 13413, 818607
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2023-06-22 |
Study Overview
Brief Summary
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019 cells) in non-Hodgkins Lymphoma (NHL) patients. The duration of active protocol intervention is approximately 24 months from screening visit. The protocol will require approximately 48 months to complete.
Official Title
Conditions
Intervention / Treatment
- Biological: CART-19
Other Study ID Numbers
- UPCC 13413, 818607